<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES
13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
(AMENDMENT NO. 1)*
LJL BioSystems, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, Par Value $0.001 Per Share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
501873 10 3
----------------------------------
(CUSIP Number)
December 31, 1999
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
/ / Rule 13d-1(b)
/ / Rule 13d-1(c)
/X/ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
<PAGE>
CUSIP No. 501873 10 3 13G Page 2 of 5 pages
------------
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
GALINA I. LEYTES
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) /X/
of a Group (See Instructions) (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
U.S.A
- -------------------------------------------------------------------------------
(5) Sole Voting Power
NUMBER OF
--------------------------------------------------
SHARES (6) Shared Voting Power
BENEFICIALLY 4,540,500 (1)
--------------------------------------------------
OWNED BY (7) Sole Dispositive Power
EACH
REPORTING --------------------------------------------------
(8) Shared Dispositive Power
PERSON
4,540,500 (1)
WITH
- -------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
4,540,500 (1)
- -------------------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions)
N/A
- -------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
35.67%(2)
- -------------------------------------------------------------------------------
(12) Type of Reporting Person (See Instructions)
IN
- -------------------------------------------------------------------------------
(1) Consists of (a) 3,619,072 shares jointly held by Lev J. Leytes and Galina
I. Leytes; (b) 850,000 shares held by Yalta Investments, L.P., a family
limited partnership wherein Mr. and Mrs. Leytes are general partners; (c)
35,714 shares held by Dina I. Leytes Irrevocable Trust, and (c) 35,714 shares
held by Mary E. Leytes Irrevocable Trust. Ms. Leytes disclaims beneficial
ownership of the shares held in each daughter's trust except to the extent of
her pecuniary interest therin.
(2) Calculated based on 12,730,000 shares outstanding as of February 7, 2000.
*SEE INSTRUCTIONS
<PAGE>
CUSIP No. 501873 10 3 13G Page 3 of 5 pages
------------
ITEM 1.
(a) Name of Issuer
LJL BioSystems, Inc.
---------------------------------------------------------------------
(b) Address of Issuer's Principal Executive Offices
405 Tasman Drive, Sunnyvale, CA 94089
---------------------------------------------------------------------
ITEM 2.
(a) Name of Person Filing
Galina I. Leytes
---------------------------------------------------------------------
(b) Address of Principal Business Office or, if none, Residence
405 Tasman Drive, Sunnyvale, CA 94089
---------------------------------------------------------------------
(c) Citizenship
U.S.A.
---------------------------------------------------------------------
(d) Title of Class of Securities
Common Stock, Par Value $0.001 Per Share
---------------------------------------------------------------------
(e) CUSIP Number
501873 10 3
---------------------------------------------------------------------
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13d-1(b) OR
240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
(a) / / Broker or dealer registered under Section 15 of the Exchange Act
(15 U.S.C. 78o).
(b) / / Bank as defined in section 3(a)(6) of the Exchange Act
(15 U.S.C. 78c).
(c) / / Insurance company as defined in section 3(a)(19) of the Act
(15 U.S.C. 78c).
(d) / / Investment company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8).
(e) / / An investment adviser in accordance with section
240.13d-1(b)(1)(ii)(E).
(f) / / An employee benefit plan or endowment fund in accordance with
section 240.13d-1(b)(1)(ii)(F).
(g) / / A parent holding company or control person in accordance with
section 240.13d-1(b)(1)(ii)(G).
(h) / / A savings association as defined in section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813).
(i) / / A church plan that is excluded from the definition of an investment
company under section 3(c)(14) of the Investment Company Act of 1940
(15 U.S.C. 80a-3).
(j) / / Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
<PAGE>
CUSIP No. 501873 10 3 13G Page 4 of 5 pages
------------
ITEM 4. OWNERSHIP
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
4,540,500 (1)
---------------------------------------------------------------------------
(b) Percent of class:
35.67%, calculated based on 12,730,000 shares outstanding as of February
7, 2000
---------------------------------------------------------------------------
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote
-----------------------------------------------------------------
(ii) Shared power to vote or to direct the vote
4,540,500 (1)
-----------------------------------------------------------------
(iii) Sole power to dispose or to direct the disposition of
-----------------------------------------------------------------
(iv) Shared power to dispose or to direct the disposition of
4,540,500 (1)
-----------------------------------------------------------------
(1) Consists of (a) 3,619,072 shares jointly held by Lev J. Leytes and Galina
I. Leytes; (b) 850,000 shares held by Yalta Investments, L.P., a family
limited partnership wherein Mr. and Mrs. Leytes are general partners; (c)
35,714 shares held by Dina I. Leytes Irrevocable Trust; and (c) 35,714 shares
held by Mary E. Leytes Irrevocable Trust. Ms. Leytes disclaims beneficial
ownership of the shares held in each daughter's trust except to the extent of
her pecuniary interest therin.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
N/A
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
3,619,072 shares jointly held by Lev J. Leytes and Galina I. Leytes,
850,000 shares held by Yalta Investments, L.P., a family limited
partnership wherein Mr. and Mrs. Leytes are general partners,
35,714 shares held by Dina I. Leytes Irrevocable Trust and 35,714
shares held by Mary E. Leytes Irrevocable Trust. Ms. Leytes
disclaims beneficial ownership of the shares held in each daughter's
trust except to the extent of her pecuniary interest therein.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
N/A
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
N/A
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
N/A
ITEM 10. CERTIFICATION.
N/A
<PAGE>
CUSIP No. 501873 10 3 13G Page 5 of 5 pages
------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 11, 2000
-------------------------------------------
Date
/s/ Galina I. Leytes
-------------------------------------------
Signature
Galina I. Leytes, Executive Vice President
-------------------------------------------
Name/Title
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is
signed on behalf of a person by his authorized representative other than an
executive officer or general partner of the filing person, evidence of the
representative's authority to sign on behalf of such person shall be filed
with the statement, provided, however, that a power of attorney for this
purpose which is already on file with the Commission may be incorporated by
reference. The name and any title of each person who signs the statement
shall be typed or printed beneath his signature.
NOTE: SCHEDULES FILED IN PAPER FORMAT SHALL INCLUDE A SIGNED ORIGINAL AND
FIVE COPIES OF THE SCHEDULE, INCLUDING ALL EXHIBITS. SEE RULE 13d-7(b) FOR
OTHER PARTIES TO WHOM COPIES ARE TO BE SENT.
ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE
FEDERAL CRIMINAL VIOLATIONS. (SEE 18 U.S.C. 1001).
